Top Stories
Amplitude Therapeutics will use its trans-amplifying RNA (taRNA) technology to discover infectious disease vaccine candidates.
The once-weekly basal insulin is still under review by the UK's Medicines and Healthcare products Regulatory Agency.
The public offering, boosted from earlier plans to raise $350 million, comes shortly after positive Phase III data for avexitide in post-bariatric hypoglycaemia.
Genglycos (pariglasgene brecaparvovec-opnr) received FDA accelerated approval to treat adults and children eight years and older with glycogen storage disease type Ia.
The startup already has a $30-million-plus co-development and licensing deal with a Fortune 100 healthcare company and is working with NVIDIA to scale its medical AI models.
Conference News
Espoo, Finland, August 20, 2026: Herantis Pharma Plc ("Herantis") a clinical-stage company developing disease-modifying therapies to stop the progression of Parkinson’s disease, releases today the Com...
NANJING, China, Aug. 19, 2026 (GLOBE NEWSWIRE) -- Nanjing Leads Biolabs Co., Ltd. (“Leads Biolabs” or the “Company,” Stock Code: 9887.HK) today announced that the full abstract of the Phase II clinica...
Adding a personalised cancer vaccine to standard-of-care immunotherapy slowed recurrence of melanoma and reduced the risk of it spreading to other parts of the body, new Phase III data has confirmed. Patients enrolled in the study had previously undergone surgery.
Real-world evidence on NSCLC treatment patterns and outcomes showcases Flatiron's unified, global oncology engineNEW YORK--(BUSINESS WIRE)-- Flatiron Health today announced its presence at the IASLC 2...
Presentation will feature results from the planned interim analysis of the Phase 3 REZILIENT3 trial, which met its primary endpoint of progression-free survival in first line EGFR exon 20 insertion mu...
